Position in GELS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,644
-$34,444 QoQ
Shares Held
10,052
-80.4% QoQ
Ownership
0.094%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#4
of 5 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GELS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026TWO SIGMA INVESTMENTS, LP holds $750,878,580 across 46 Drug Manufacturers - Specialty & Generic names. GELS ranks #46 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
3,060,570 | $403,199,491 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
6,392,628 | $60,857,818 | |
| 3 | ALKS |
Alkermes plc.
|
780,683 | $27,604,950 | |
| 4 | ESPR |
Esperion Therapeutics, Inc.
|
9,458,779 | $25,917,054 | |
| 5 | LQDA |
Liquidia Corp
|
563,233 | $21,256,413 | |
| 6 | IRWD |
Ironwood Pharmaceuticals Inc
|
5,848,276 | $20,527,448 | |
| 7 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
420,914 | $20,267,009 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
|
590,116 | $19,515,136 |
All Filings in GELS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,644 | 10,052 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $41,088 | 51,361 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||